Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin

por Yu, Huan, Woo, Vincent C
Publicado 2017

Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes

por Gough, Stephen CL, Jain, Rajeev, Woo, Vincent C
Publicado 2016

Greater Combined Reductions of HbA(1c) ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators

por Dungan, Kathleen M., Bardtrum, Lars, Christiansen, Erik, Eliasson, Johanna, Mellbin, Linda, Woo, Vincent C., Vilsbøll, Tina
Publicado 2023

IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test

por Holst, Jens J., Buse, John B., Rodbard, Helena W., Linjawi, Sultan, Woo, Vincent C., Boesgaard, Trine Welløv, Kvist, Kajsa, Gough, Stephen C.
Publicado 2015

Abstract 15: Glycemic and body weight responses to oral semaglutide in the PIONEER trial program

por Kumar, K B Sharan, Dungan, Kathleen M, Hertz, Christin L, Mellibin, Linda, Nielsen, Morten Abildlund, Sorrig, Rasmus, Woo, Vincent C, Vilsboll, Tina
Publicado 2022

Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real‐world setting

por Seaquist, Elizabeth R., Dulude, Hélène, Zhang, Xiaotian M., Rabasa‐Lhoret, Remi, Tsoukas, George M., Conway, James R., Weisnagel, Stanley J., Gerety, Gregg, Woo, Vincent C., Zhang, Shuyu, Carballo, Dolorès, Pradhan, Sheetal, Piché, Claude A., Guzman, Cristina B.
Publicado 2018